Pointing to a growing demand for seasonal flu vaccines in Japan, Takeda has signed on with the Chemo-Sero Therapeutic Research Institute (Kaketsuken) to sell one of the institute's seasonal shots while it continues distribution of another.
The threat of a smallpox outbreak is an ongoing concern that's helped Bavarian Nordic pay its bills through the years. With an announcement Wednesday trumpeting two successful late-stage tests, the company has reason to believe it can advance its business with smallpox vaccine Imvamune. Read more >>
A lot of people make news in the biopharma business. Few of them are influential. Influence, simply put, is the ability to make your mark in such a way as to get other prominent people in this business to rethink the way they do business. The people on this year's list of influentials are doing everything from helping change the metrics on R&D performance, crusading new technologies and redefining biotech in a boom, to trying to forge a new definition for Big Pharma--still a hot topic after many of the old definitions failed to generate real growth. Read more >>
POPULAR COMMENT THREADS
There is no cure for genital herpes, but Genocea is getting closer to marketing an immunotherapy that could control herpes symptoms. The Massachusetts-based company announced Wednesday that it met its goals in a Phase II study of its investigational GEN-003 vaccine.
Oxford-based PsiOxus closed a Series C financing round, scoring £25 million ($39 million) to advance its lead candidate, enadenotucirev, an oncolytic virus aimed at fighting colorectal tumors. The funding came from GlaxoSmithKline's VC unit and U.K. heavyweight investor Neil Woodford's new $1.2 billion fund.
With ambitious plans for the next year, Ahmedabad-based Zydus Cadila's coming launches could alter the vaccines landscape in India and challenge established players there.
After a troublesome flu vaccine season, the NIH has announced that it'll lend a hand to Vanderbilt University as researchers there attempt to develop an improved, "universal" vaccine against the virus.
Medicago is building a $200 million manufacturing facility in Quebec City, where it will use plant technology to produce vaccines against Ebola and other viruses.
In a big week for Ebola vaccines, Emergent Biosciences and GlaxoSmithKline have begun a Phase I trial of their candidates, while Bavarian Nordic received €50 million ($56 million) in loans from the European Investment Bank that go in part toward its programs in Ebola and infectious diseases.
From Our Sister Sites
A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a...
The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.